Ålandsbanken Abp: Återköp av egna aktier 16.11.2022
| Ålandsbanken Abp |
Förändringar i återköpta aktier
16.11.2022 kl. 18:30 EET
Ålandsbanken Abp: Återköp av egna aktier 16.11.2022
| Datum | 16.11.2022 | |
| Handelsplats Börsaffär | Nasdaq Helsinki Oy (XHEL) Köp | |
| Aktie klass | ALBBV | |
| Antal | 193 | st. |
| Medelpris/aktie | 32,6073 | EUR |
| Högsta pris/aktie | 32,8000 | EUR |
| Lägsta pris/aktie | 32,6000 | EUR |
| Totalt pris | 6 293,21 | EUR |
Ålandsbanken Abp:s innehav av egna aktier 16.11.2022:
ALBBV 13 931 | st. |
På Ålandsbanken Abp:s vägnar
Skandinaviska Enskilda Banken AB (Publ)
Antti Salakka Janne Tiihonen
För vidare information vänligen kontakta:
Peter Wiklöf, Vd och koncernchef, Ålandsbanken Abp, tfn +358 40 512 7505
Bilaga
För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.
Om
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Följ GlobeNewswire by notified
Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.
Senaste pressmeddelandena från GlobeNewswire by notified
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®6.5.2024 14:30:00 CEST | Press release
OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production of our commercial-sized manufacturing process for Ampligen represents a critical component of our overall development, commercial and business development strategies. This is an important milestone as we look to advance our pipeline and work toward clinical and commercial success. Our record of successful manufacturing is both important as we seek commercial partners, as well as for establishing Ampligen reserves for ongoing and upcoming clinical trials.” Ampligen is currently being evaluated as
Investeringsforeningen IA Invest, Afdeling Thygesen Global Stock Selection – Endeligt resultat af tegning6.5.2024 14:23:30 CEST | pressemeddelelse
Investeringsforeningen IA Invest havde indledende tegningsperiode i afdeling Thygesen Global Stock Selection (ISIN: DK0062842134) fra den 22. april til og med den 3. maj 2024. Efter opgørelse af tegningsresultatet for afdeling Thygesen Global Stock Selection er det vurderingen, at afdelingen ikke har opnået en tilstrækkelig stor formue til at blive lanceret og optaget til handel på Nasdaq Copenhagen. Der vil som følge heraf ikke blive udstedt andele i afdeling Thygesen Global Stock Selection. Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til undertegnede på telefon 38 14 66 00. Med venlig hilsen Niels Erik Eberhard Direktør
Investeringsforeningen IA Invest, Afdeling Furesø Globale Kvalitetsaktier – Endeligt resultat af tegning6.5.2024 14:20:15 CEST | pressemeddelelse
Investeringsforeningen IA Invest havde indledende tegningsperiode i følgende afdeling fra den 22. april til og med den 3. maj 2024. Endeligt resultat af tegningen fremgår nedenfor: AfdelingISINTegningskursAntal investorerAntal cirkulerende andeleFormue kr.Furesø Globale KvalitetsaktierDK0062842217100,2033425.234 42.608.447 De nye andele vil blive optaget til handel på Nasdaq Copenhagen med første handelsdag den 14. maj 2024. For yderligere information henvises der til henholdsvis foreningens og afdelingens hjemmeside www.iainvest.dk og www.furesoekapital.dk. Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til undertegnede på telefon 38 14 66 00. Med venlig hilsen Niels Erik Eberhard Direktør
Exodus Movement, Inc. Announces Uplist to NYSE American Exchange6.5.2024 14:15:00 CEST | Press release
OMAHA, Neb., May 06, 2024 (GLOBE NEWSWIRE) -- Exodus Movement, Inc. (OTCQX: EXOD) (“Exodus” or the “Company”), the leading self-custodial cryptocurrency software platform, today announced that its common stock has been approved for listing on the NYSE American stock exchange. The Company’s Class A common stock, par value $0.000001 (the “Common Stock”), will begin trading on the NYSE American under its current symbol, “EXOD,” at the open of trading on May 9, 2024. The Common Stock will continue to trade on the OTCQX until the close of market on May 8, 2024. Current stockholders of the Company do not need to take any action prior to the Company’s expected listing on the NYSE American. “Uplisting to the NYSE American marks a significant milestone in our journey. Trading on the NYSE American will allow Exodus to create greater long-term value for our stockholders by increasing our presence within the investor community and, in turn, increase liquidity,” said JP Richardson, CEO and co-found
Wolters Kluwer unveils AI center; Provides direct access to its AI-driven solutions, insights and expertise6.5.2024 14:01:56 CEST | Press release
PRESS RELEASE Wolters Kluwer unveils AI center; Provides direct access to its AI-driven solutions, insights and expertise Alphen aan den Rijn – May 6, 2024 – Wolters Kluwer, a global leader in professional information, software solutions, and services, today unveiled its dedicated AI center. The launch marks the company's ongoing commitment to combining deep domain knowledge with cutting-edge technology such as artificial intelligence (AI), which Wolters Kluwer has been incorporating into its products for the last 10 years. The AI center centralizes the company’s latest AI-insights, research, and AI-driven information solutions in one accessible location, catering to professionals across critical sectors such as health, financial services, legal, ESG, risk, regulatory, and compliance. The site launch includes a recently published fireside chat featuring Wolters Kluwer CEO and Chair of the Executive Board, Nancy McKinstry, on the explosion of AI in the professional sector. Nancy McKinst